Sacituzumab Govitecan Aids Unmet Need in Pretreated HR+, HER2– Breast Cancer

Video

An expert from Dana-Farber Cancer Institute highlights the unmet needs that sacituzumab govitecan meets in the treatment of advanced hormone receptor-positive, HER2-negative breast cancer.

The unmet needs previously seen in heavily pretreated hormone receptor (HR)-positive, HER2-negative breast cancer may resolve with the use and implementation of sacituzumab govitecan (Trodelvy) treatment, according to Sara M. Tolaney, MD, MPH.

CancerNetwork® spoke with Tolaney, chief of the Division of Breast Oncology and associate director of the Susan F. Smith Center for Women’s Cancer at Dana-Farber Cancer Institute, and associate professor of medicine at Harvard Medical School, in Boston, ahead of the FDA’s approval of sacituzumab govitecan to treat patients with advanced HR-positive, HER2-negative breast cancer.

According to Tolaney, alternative methods of treatment for HR-positive, HER2-negative breast cancer, including CDK4/6 inhibitors and oral selective estrogen receptor degraders (SERDs), do not provide enduring benefits to this patient population who received prior endocrine therapy or chemotherapy. She suggested that the FDA approval of sacituzumab, however, will address an unmet need by providing additional benefits to a population of heavily pretreated patients.

Transcript:

There really is an unmet need in heavily pretreated hormone receptor-positive, [HER2-negative] disease. We've made great strides in improving outcomes for this patient population. We have CDK4/6 inhibitors. Soon we will have multiple other targeted agents like oral SERDs and AKT inhibitors. And I've even seen another antibody drug conjugate, trastuzumab deruxtecan [Enhertu], enter this space for the two-thirds of patients who [have] HER2-low [disease]. Despite having all these agents available, what we find is that once patients get through standard endocrine therapy and 1 or 2 lines of chemotherapy, unfortunately, that's where we start to get into trouble with very a short duration of benefit to treatment. Using sacituzumab in this space is really addressing an unmet need that we have in this population.

Reference

U.S FDA approves Trodelvy in pre-treated HR+/HER2- metastatic breast cancer. News release. Gilead. February 3, 2023. Accessed February 3, 2023. https://bwnews.pr/3Y0bftX

Recent Videos
Shwetal Mehta, PhD, describes efforts regarding the development of protein degraders and antibody-drug conjugates in the neuro-oncology field.
Liquid biopsy tests may help determine the extent of activity among patients who receive a novel fourth-generation EGFR inhibitor for brain cancer.
Shwetal Mehta, PhD, highlights novel brain cancer drug development procedures in the clinical lab and pre-clinical arms of the Ivy Brain Tumor Center.
Observing changes in the tumor microenvironment before and after a biopsy may elucidate how kidney cancer cells interact with immune cells.
Various kidney cancer trials have combined agents such as A2a receptor inhibitors with immunotherapy backbones to potentially improve treatment outcomes.
Leveraging novel agents, innovative clinical trial designs, and correlative studies may improve the treatment of patients with kidney cancer.
Sympathomimetic effects related to psilocybin may preclude use among patients with coronary artery disease or those with a high risk of stroke.
Psilocybin-assisted psychotherapy may be integrated into pre-existing behavioral health aspects of comprehensive cancer treatment.
Psilocybin may help address a need for effective medication to aid those who have psychological challenges related to a serious cancer diagnosis.
Related Content